UROV News and Press, Urovant Sciences Ltd. From 11/12/20

Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant - Sumitovant Biopharma to acquire all outstanding shares of Urovant it does not already own - Transaction increases Urovant's ability to provide patient therapies and ac...

Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday, November 17, 2020, at the Jefferies Virtual London Healthcare Conference. A live, audi...

Image source: The Motley Fool. UROVANT SCIENCES LTD (NASDAQ: UROV) Q2 2020 Earnings Call Nov 02, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: UROVANT SCIENCES LTD (UROV) Q2 2020 Earnings Call Transcript

Urovant Sciences Ltd. (UROV) Q2 2020 Earnings Conference Call November 2, 2020 4:30 PM ET Company Participants Ryan Kubota – Investor Relations Jim Robinson – President and Chief Executive Officer Ajay Bansal – Chief Financial Officer Cornelia Haag-Molkenteller – C...

Urovant Sciences (UROV): FQ2 GAAP EPS of -$1.12 beats by $0.30.Cash of $74.4M.Press Release For further details see: Urovant Sciences EPS beats by $0.30

Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended September 30, 2020. During the second quarter of fiscal year 2020, the Company achieved a number of significant operational and commercial planning milestones in preparation for the U.S...

Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2020. Management will host a conference call to discuss Urovant’s financi...

Urovant Sciences (UROV) has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment, after receiving FDA approval for the drug. In March, the FDA accepted vibegron application for overactive bl...

Agreement will supplement Urovant’s targeted sales and market access efforts in the launch of vibegron by expanding the outreach to Primary Care Physicians and their patients Urovant Sciences (Nasdaq: UROV) today announced it has entered into a five-year U.S. co-promo...

Urovant Sciences' ( UROV ) share price has been hit through the coronavirus in 2020 and has not been rising despite the company expecting approval for its main asset Vibegron on December 26, 2020. Furthermore, with sell-side consensus with potential sales peak over $600 M and an overseeable ...